Top cited articles

Acceptance rate


Time to first decision

26 days*

Time from acceptance to publication

15 days*

Impact Factor




Interferon pathway in SLE: one key to unlocking the mystery of the disease
Ronnblom, Lars; Leonard, Dag

Type I interferons in host defence and inflammatory diseases
Crow, Mary K.; Ronnblom, Lars

Changing paradigms in the treatment of systemic lupus erythematosus
Fanouriakis, Antonis; Bertsias, George

Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE
Petri, Michelle A.; Conklin, John; O’Malley, Tyler; Dervieux, Thierry

Targeting mitochondrial oxidative stress with MitoQ reduces NET formation and kidney disease in lupus-prone MRL-lpr mice
Fortner, Karen A.; Blanco, Luz P.; Buskiewicz, Iwona. et al

Measurement properties of selected patient-reported outcome measures for use in randomised controlled trials in patients with systemic lupus erythematosus: a systematic review
Strand, Vibeke; Simon, Lee S.; Meara, Alexa Simon; Touma, Zahi

Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE
Mcmahon, Maureen; Skaggs, Brian; Grossman, Jennifer. et al

10 most important contemporary challenges in the management of SLE
Felten, Renaud; Sagez, Flora; Gavand, Pierre-Edouard. et al

First use of cenerimod, a selective S1P(1) receptor modulator, for the treatment of SLE: a double-blind, randomised, placebo-controlled, proof-of-concept study
Hermann, Viktoria; Batalov, Anastas; Smakotina, Svetlana. et al

Urine TWEAK level as a biomarker for early response to treatment in active lupus nephritis: a prospective multicentre study
Suttichet, Thitima Benjachat; Kittanamongkolchai, Wonngarm; Phromjeen, Chutipha. et al

Prediction of prognosis and renal outcome in lupus nephritis
Parodis, Ioannis; Tamirou, Farah; Houssiau, Frederic A.

Similar progression of carotid intima-media thickness in 7-year surveillance of patients with mild SLE and controls, but this progression is still promoted by dyslipidaemia, lower HDL levels, hypertension, history of lupus nephritis and a higher prednisolone usage in patients
Ajeganova, Sofia; Gustafsson, Thomas; Lindberg, Linnea; Hafstrom, Ingiald; Frostegard, Johan

Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways
Doerner, Thomas; Tanaka, Yoshiya; Petri, Michelle A. et al

Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE
Wallace, Daniel J.; Alexander, Roberta Vezza; O’Malley, Tyler. et al

SLE: reconciling heterogeneity
Lockshin, Michael D.; Barbhaiya, Medha; Izmirly, Peter; Buyon, Jill P.; Crow, Mary K.

Prevalence of progressive multifocal leukoencephalopathy (PML) in adults and children with systemic lupus erythematosus
Kapoor, Teja; Mahadeshwar, Pooja; Hui-Yuen, Joyce. et al

Towards a practical management of fatigue in systemic lupus erythematosus
Mertz, Philippe; Schlencker, Aurelien; Schneider, Matthias. et al

Lupus serum induces inflammatory interaction with neutrophils in human glomerular endothelial cells
Russell, Dayvia A.; Markiewicz, Margaret; Oates, Jim C.

Neutrophil and lymphocyte counts are associated with different immunopathological mechanisms in systemic lupus erythematosus
Han, Bobby Kwanghoon; Wysham, Katherine D.; Cain, Kevin C. et al

Thoughts on COVID-19 and autoimmune diseases
Askanase, Anca D.; Khalili, Leila; Buyon, Jill P.